Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors

Jeremy M. O'Connor, Kathi Seidl-Rathkopf, Aracelis Z. Torres, Paul You, Kenneth R. Carson, Joseph S. Ross, Cary P. Gross

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment. However, among patients with NSCLC, males had significantly higher odds of receiving anti-PD1 treatment compared with females (odds ratio 1.13, 95% confidence interval 1.02–1.24, p =.02). This finding suggests that as anti-PD1 agents enter the market to transform patient care, it will be critical to monitor for disparities in the use of these drugs.

Original languageEnglish
Pages (from-to)1388-1390
Number of pages3
JournalOncologist
Volume23
Issue number11
DOIs
StatePublished - Nov 2018

Fingerprint Dive into the research topics of 'Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors'. Together they form a unique fingerprint.

  • Cite this

    O'Connor, J. M., Seidl-Rathkopf, K., Torres, A. Z., You, P., Carson, K. R., Ross, J. S., & Gross, C. P. (2018). Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. Oncologist, 23(11), 1388-1390. https://doi.org/10.1634/theoncologist.2017-0673